Type:Tablet
Generic Name:Pitavastatin
Manufacturer:Square Pharmaceuticals PLC.
Price:৳10.03
Hypercholesterolaemia, Hyperlipidaemias, Mixed dyslipidaemia, Cardiovascular disease,
May be taken with or without food.
Oral Hypercholesterolemia Adult: 2 mg once daily. May increase to 4 mg qDay if necessary. Hepatic Impairment Contraindicated in active liver disease or unexplained transaminase elevations
Safety and efficacy not established
Renal impairment: Moderate to severe (CrCl 15-60 mL/min, not on haemodialysis) and ESRD (on haemodialysis): Initial: 1 mg once daily. Max: 2 mg once daily.
Patients with a known hypersensitivity to any component of this products. Pitavastatin is contraindicated in patients with active liver disease , which may include unexplained persistent elevations of hepatic transaminase levels.
HMG-CoA reductase inhibitor, inhibits rate-limiting step in cholesterol biosynthesis by competitively inhibiting HMG-CoA reductase
Patient w/ predisposing factors for myopathy; alcoholism. Renal impairment. Monitoring Parameters Monitor lipid panel (total cholesterol, HDL, LDL, triglycerides), hepatic transaminase levels; creatine phosphokinase (CPK). Lactation: Contraindicated
Liver enzyme abnormalities, myalgia, muscle spasm, back pain, diarrhoea, constipation, pain in extremities, arthralgia, headache, dizziness, influenza, nasopharyngitis, abdominal discomfort, abdominal pain, dyspepsia, nausea, asthenia, malaise, fatigue, hepatitis, jaundice, hypoaesthesia, insomnia, depression, interstitial lung disease, erectile dysfunction, cognitive impairment (e.g. memory loss and impairment, confusion, forgetfulness, amnesia). Potentially Fatal: Myopathy and rhabdomyolysis w/ acute renal failure secondary to myoglobinuria; hepatic failure.
Increased bioavailability w/ erythromycin and rifampicin. Increased risk of myopathy/rhabdomyolysis w/ gemfibrozil, colchicine, niacin and other fibrates. Potentially Fatal: Ciclosporin significantly increases pitavastatin exposure.
